{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T20:44:35Z","timestamp":1793047475610,"version":"4.5.0"},"reference-count":26,"publisher":"American Medical Association (AMA)","issue":"16","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA"],"published-print":{"date-parts":[[2023,4,25]]},"abstract":"<jats:sec><jats:title>Importance<\/jats:title><jats:p>The effect of rationally defined nonpathogenic, nontoxigenic, commensal strains of Clostridia on prevention of <jats:italic>Clostridioides difficile<\/jats:italic> infection (CDI) is unknown.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objective<\/jats:title><jats:p>To determine the efficacy of VE303, a defined bacterial consortium of 8 strains of commensal Clostridia, in adults at high risk for CDI recurrence. The primary objective was to determine the recommended VE303 dosing for a phase 3 trial.<\/jats:p><\/jats:sec><jats:sec><jats:title>Design, Setting, and Participants<\/jats:title><jats:p>Phase 2, randomized, double-blind, placebo-controlled, dose-ranging study conducted from February 2019 to September 2021 at 27 sites in the US and Canada. The study included 79 participants aged 18 years or older who were diagnosed with laboratory-confirmed CDI with 1 or more prior CDI episodes in the last 6 months and those with primary CDI at high risk for recurrence (defined as aged \u226575 years or \u226565 years with \u22651 risk factors: creatinine clearance &amp;amp;lt;60 mL\/min\/1.73 m<jats:sup>2<\/jats:sup>, proton pump inhibitor use, remote [&amp;amp;gt;6 months earlier] CDI history).<\/jats:p><\/jats:sec><jats:sec><jats:title>Interventions<\/jats:title><jats:p>Participants were randomly assigned to high-dose VE303 (8.0\u2009\u00d7\u200910<jats:sup>9<\/jats:sup> colony-forming units [CFUs]) (n\u2009=\u200930), low-dose VE303 (1.6\u2009\u00d7\u200910<jats:sup>9<\/jats:sup> CFUs) (n\u2009=\u200927), or placebo capsules (n\u2009=\u200922) orally once daily for 14 days.<\/jats:p><\/jats:sec><jats:sec><jats:title>Main Outcomes and Measures<\/jats:title><jats:p>The primary efficacy end point was the proportion of participants with CDI recurrence at 8 weeks using a combined clinical and laboratory definition. The primary efficacy end point was analyzed in 3 prespecified analyses, using successively broader definitions for an on-study CDI recurrence: (1) diarrhea consistent with CDI plus a toxin-positive stool sample; (2) diarrhea consistent with CDI plus a toxin-positive, polymerase chain reaction\u2013positive, or toxigenic culture\u2013positive stool sample; and (3) diarrhea consistent with CDI plus laboratory confirmation or (in the absence of a stool sample) treatment with a CDI-targeted antibiotic.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Baseline characteristics were similar across the high-dose VE303 (n\u2009=\u200929; 1 additional participant excluded from efficacy analysis), low-dose VE303 (n\u2009=\u200927), and placebo (n\u2009=\u200922) groups. The participants\u2019 median age was 63.5 years (range, 24-96); 70.5% were female; and 1.3% were Asian, 1.3% Black, 2.6% Hispanic, and 96.2% White. CDI recurrence rates through week 8 (using the efficacy analysis 3 definition) were 13.8% (4\/29) for high-dose VE303, 37.0% (10\/27) for low-dose VE303, and 45.5% (10\/22) for placebo (<jats:italic>P<\/jats:italic>\u2009=\u2009.006, high-dose VE303 vs placebo).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions and Relevance<\/jats:title><jats:p>Among adults with laboratory-confirmed CDI with 1 or more prior CDI episodes in the last 6 months and those with primary CDI at high risk for recurrence, high-dose VE303 prevented recurrent CDI compared with placebo. A larger, phase 3 study is needed to confirm these findings.<\/jats:p><\/jats:sec><jats:sec><jats:title>Trial Registration<\/jats:title><jats:p>ClinicalTrials.gov Identifier: <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT03788434\">NCT03788434<\/jats:ext-link><\/jats:p><\/jats:sec>","DOI":"10.1001\/jama.2023.4314","type":"journal-article","created":{"date-parts":[[2023,4,15]],"date-time":"2023-04-15T15:00:28Z","timestamp":1681570828000},"page":"1356","source":"Crossref","is-referenced-by-count":221,"title":["VE303, a Defined Bacterial Consortium, for Prevention of Recurrent <i>Clostridioides difficile<\/i> Infection"],"prefix":"10.1001","volume":"329","author":[{"given":"Thomas","family":"Louie","sequence":"first","affiliation":[{"name":"University of Calgary and Foothills Medical Centre, Calgary, Alberta, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoav","family":"Golan","sequence":"additional","affiliation":[{"name":"Tufts Medical Center, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sahil","family":"Khanna","sequence":"additional","affiliation":[{"name":"Mayo Clinic, Rochester, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dmitri","family":"Bobilev","sequence":"additional","affiliation":[{"name":"Vedanta Biosciences Inc, Cambridge, Massachusetts"},{"name":"Fusion Pharmaceuticals, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathalie","family":"Erpelding","sequence":"additional","affiliation":[{"name":"Vedanta Biosciences Inc, Cambridge, Massachusetts"},{"name":"Bicycle Therapeutics, Cambridge, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Candida","family":"Fratazzi","sequence":"additional","affiliation":[{"name":"Vedanta Biosciences Inc, Cambridge, Massachusetts"},{"name":"Boston Biotech Clinical Research, Natick, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meg","family":"Carini","sequence":"additional","affiliation":[{"name":"Vedanta Biosciences Inc, Cambridge, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajita","family":"Menon","sequence":"additional","affiliation":[{"name":"Vedanta Biosciences Inc, Cambridge, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary","family":"Ruisi","sequence":"additional","affiliation":[{"name":"Vedanta Biosciences Inc, Cambridge, Massachusetts"},{"name":"C4 Therapeutics, Watertown, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason M.","family":"Norman","sequence":"additional","affiliation":[{"name":"Vedanta Biosciences Inc, Cambridge, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremiah J.","family":"Faith","sequence":"additional","affiliation":[{"name":"Icahn School of Medicine at Mount Sinai, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernat","family":"Olle","sequence":"additional","affiliation":[{"name":"Vedanta Biosciences Inc, Cambridge, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minran","family":"Li","sequence":"additional","affiliation":[{"name":"Cytel Inc, Cambridge, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey L.","family":"Silber","sequence":"additional","affiliation":[{"name":"Vedanta Biosciences Inc, Cambridge, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darrell S.","family":"Pardi","sequence":"additional","affiliation":[{"name":"Mayo Clinic, Rochester, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"14","key":"jpc230002r1","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1056\/NEJMoa1910215","article-title":"Trends in US burden of Clostridioides difficile infection and outcomes.","volume":"382","author":"Guh","year":"2020","journal-title":"N Engl J Med"},{"issue":"4","key":"jpc230002r2","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1097\/EDE.0000000000000119","article-title":"Hospital-acquired Clostridium difficile infections: estimating all-cause mortality and length of stay.","volume":"25","author":"Lofgren","year":"2014","journal-title":"Epidemiology"},{"issue":"8","key":"jpc230002r3","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1038\/ajg.2014.167","article-title":"The evolution of urban C difficile infection (CDI): CDI in 2009-2011 is less severe and has better outcomes than CDI in 2006-2008.","volume":"109","author":"Feuerstadt","year":"2014","journal-title":"Am J Gastroenterol"},{"issue":"6","key":"jpc230002r4","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1053\/j.gastro.2014.01.059","article-title":"Role of the intestinal microbiota in resistance to colonization by Clostridium difficile.","volume":"146","author":"Britton","year":"2014","journal-title":"Gastroenterology"},{"key":"jpc230002r5","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1111\/1469-0691.12046","article-title":"Can we identify patients at high risk of recurrent Clostridium difficile infection?","volume":"18","author":"Kelly","year":"2012","journal-title":"Clin Microbiol Infect"},{"issue":"5","key":"jpc230002r6","doi-asserted-by":"publisher","first-page":"e1029","DOI":"10.1093\/cid\/ciab549","article-title":"Clinical Practice Guideline by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA): 2021 focused update guidelines on management of Clostridioides difficile infection in adults.","volume":"73","author":"Johnson","year":"2021","journal-title":"Clin Infect Dis"},{"issue":"6","key":"jpc230002r7","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.14309\/ajg.0000000000001278","article-title":"ACG clinical guidelines: prevention, diagnosis, and treatment of Clostridioides difficile infections.","volume":"116","author":"Kelly","year":"2021","journal-title":"Am J Gastroenterol"},{"key":"jpc230002r8","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/j.cmi.2021.09.038","article-title":"European Society of Clinical Microbiology and Infectious Diseases: 2021 update on the treatment guidance document for Clostridioides difficile infection in adults.","volume":"27","author":"van Prehn","year":"2021","journal-title":"Clin Microbiol Infect"},{"issue":"21","key":"jpc230002r9","doi-asserted-by":"publisher","first-page":"2043","DOI":"10.1056\/NEJMoa1910437","article-title":"Drug-resistant E coli bacteremia transmitted by fecal microbiota transplant.","volume":"381","author":"DeFilipp","year":"2019","journal-title":"N Engl J Med"},{"issue":"11","key":"jpc230002r10","doi-asserted-by":"publisher","first-page":"e876","DOI":"10.1093\/cid\/ciaa1486","article-title":"Shiga toxin-producing Escherichia coli transmission via fecal microbiota transplant.","volume":"72","author":"Zellmer","year":"2021","journal-title":"Clin Infect Dis"},{"issue":"11","key":"jpc230002r11","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1038\/nbt.4287","article-title":"Translating microbiome futures.","volume":"36","author":"Taroncher-Oldenburg","year":"2018","journal-title":"Nat Biotechnol"},{"issue":"3","key":"jpc230002r12","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1056\/NEJMoa2106516","article-title":"SER-109, an oral microbiome therapy for recurrent Clostridioides difficile infection.","volume":"386","author":"Feuerstadt","year":"2022","journal-title":"N Engl J Med"},{"issue":"5","key":"jpc230002r13","doi-asserted-by":"publisher","DOI":"10.1016\/S2666-5247(22)00096-9","article-title":"Microbiome therapy for recurrent Clostridioides difficile.","volume":"3","author":"Gilbert","year":"2022","journal-title":"Lancet Microbe"},{"issue":"15","key":"jpc230002r14","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.1007\/s40265-022-01797-x","article-title":"Efficacy and safety of RBX2660 in PUNCH CD3, a phase III, randomized, double-blind, placebo-controlled trial with a bayesian primary analysis for the prevention of recurrent Clostridioides difficile infection.","volume":"82","author":"Khanna","year":"2022","journal-title":"Drugs"},{"issue":"4","key":"jpc230002r15","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1016\/j.chom.2022.03.016","article-title":"Colonization of the live biotherapeutic product VE303 and modulation of the microbiota and metabolites in healthy volunteers.","volume":"30","author":"Dsouza","year":"2022","journal-title":"Cell Host Microbe"},{"key":"jpc230002r17","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2020.100642","article-title":"Faecal microbiota transplantation for recurrent Clostridioides difficile infection: an updated systematic review and meta-analysis.","volume":"29-30","author":"Baunwall","year":"2020","journal-title":"EClinicalMedicine"},{"issue":"4","key":"jpc230002r18","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1056\/NEJMoa1602615","article-title":"Bezlotoxumab for prevention of recurrent Clostridium difficile infection.","volume":"376","author":"Wilcox","year":"2017","journal-title":"N Engl J Med"},{"issue":"suppl 2","key":"jpc230002r19","doi-asserted-by":"publisher","first-page":"S154","DOI":"10.1093\/cid\/cis462","article-title":"Treatment of first recurrence of Clostridium difficile infection: fidaxomicin versus vancomycin.","volume":"55","author":"Cornely","year":"2012","journal-title":"Clin Infect Dis"},{"issue":"5","key":"jpc230002r20","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1056\/NEJMoa0910812","article-title":"Fidaxomicin versus vancomycin for Clostridium difficile infection.","volume":"364","author":"Louie","year":"2011","journal-title":"N Engl J Med"},{"issue":"6","key":"jpc230002r21","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1093\/cid\/ciab233","article-title":"A tapered-pulsed fidaxomicin regimen following treatment in patients with multiple Clostridioides difficile infection recurrences.","volume":"73","author":"Skinner","year":"2021","journal-title":"Clin Infect Dis"},{"issue":"2","key":"jpc230002r22","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.jhin.2015.10.024","article-title":"Adverse events in faecal microbiota transplant: a review of the literature.","volume":"92","author":"Baxter","year":"2016","journal-title":"J Hosp Infect"},{"issue":"2","key":"jpc230002r23","first-page":"150","article-title":"Adverse events in fecal microbiota transplantation: a systematic review and meta-analysis.","volume":"35","author":"Rapoport","year":"2022","journal-title":"Ann Gastroenterol"},{"issue":"11","key":"jpc230002r24","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pbio.0060280","article-title":"The pervasive effects of an antibiotic on the human gut microbiota, as revealed by deep 16S rRNA sequencing.","volume":"6","author":"Dethlefsen","year":"2008","journal-title":"PLoS Biol"},{"issue":"10","key":"jpc230002r25","doi-asserted-by":"publisher","first-page":"4182","DOI":"10.1172\/JCI72336","article-title":"Clostridium difficile and the microbiota.","volume":"124","author":"Seekatz","year":"2014","journal-title":"J Clin Invest"},{"issue":"2","key":"jpc230002r26","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofu048","article-title":"Determinants of Clostridium difficile infection incidence across diverse United States geographic locations.","volume":"1","author":"Lessa","year":"2014","journal-title":"Open Forum Infect Dis"},{"key":"jpc230002r16","unstructured":"US Food and Drug Administration. FDA guidance on conduct of clinical trials of medical products during the COVID-19 public health emergency. Published August 2021. Accessed July 1, 2022. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/fda-guidance-conduct-clinical-trials-medical-products-during-covid-19-public-health-emergency"}],"container-title":["JAMA"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/articlepdf\/2803996\/jama_louie_2023_pc_230002_1681934410.2413.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,25]],"date-time":"2023-04-25T15:45:57Z","timestamp":1682437557000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/fullarticle\/2803996"}},"subtitle":["A Randomized Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2023,4,25]]},"references-count":26,"journal-issue":{"issue":"16","published-print":{"date-parts":[[2023,4,25]]}},"URL":"https:\/\/doi.org\/10.1001\/jama.2023.4314","relation":{},"ISSN":["0098-7484"],"issn-type":[{"value":"0098-7484","type":"print"}],"subject":[],"published":{"date-parts":[[2023,4,25]]}}}